A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before



Status:Completed
Conditions:Lung Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:6/3/2018
Start Date:March 2009
End Date:May 2012

Use our guide to learn which trials are right for you!

Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

The purpose of this study is to determine the number of participants whose cancer shrinks or
disappears after treatment on the study.

Participants with Stage IIIb or IV non-small cell lung cancer (NSCLC) who have not received
previous chemotherapy will be stratified, based on disease histology (squamous versus [vs.]
nonsquamous).

Inclusion Criteria:

- Has histologically or cytologically confirmed, Stage IIIb - IV NSCLC

- Has metastatic disease

- Has a tumor measurable according to Response Evaluation Criteria in Solid Tumors
(RECIST)

- Has adequate hematologic function

- Has adequate hepatic function

- Has adequate renal function

- Women of childbearing potential must agree to use adequate contraception (hormonal or
barrier method of birth control; abstinence) prior to study entry and for the duration
of study participation

Exclusion Criteria:

- Has uncontrolled brain metastases

- Has leptomeningeal disease

- Has received previous chemotherapy for NSCLC (participants who have received adjuvant
chemotherapy are eligible if the last administration of the prior adjuvant regimen
occurred at least 6 months prior to randomization)

- Receiving any other investigational agent(s)

- Has a history of treatment with other agents targeting the insulin-like growth factor
(IGF) or the epidermal growth factor (EGF) receptor

- Has a known allergy / history of hypersensitivity reaction to any of the treatment
components

- Has poorly controlled diabetes mellitus. Participants with a history of diabetes
mellitus are allowed to participate, provided that their blood glucose is within
normal range [fasting glucose <160 milligrams per deciliter (mg/dL) or below the upper
limit of normal (ULN) and hemoglobin A1C≤ 7%] and that they are on a stable dietary or
therapeutic regimen for this condition

- Has an uncontrolled intercurrent illness

- Pregnant or lactating

- Has a history of another primary cancer, with the exception of: a) curatively resected
nonmelanomatous skin cancer; b) curatively treated cervical carcinoma in situ; or c)
other primary solid tumor treated with curative intent and no known active disease
present and no treatment administered during the last 3 years

- Has superior vena cava syndrome contraindicating hydration

- Has current clinically-relevant coronary artery disease (New York Heart Association
III or IV) or uncontrolled congestive heart failure

- Has any National Cancer Institute Common Toxicity Criteria for Adverse Events
(NCI-CTCAE) Version (v) 3.0 Grade ≥2 peripheral neuropathy

- Has significant third space fluid retention, requiring repeated drainage
We found this trial at
9
sites
Anniston, Alabama 36207
?
mi
from
Anniston, AL
Click here to add this to my saved trials
Albuquerque, New Mexico 87131
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Atlanta, Georgia 30341
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Chicago, Illinois 60076
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Cincinnati, Ohio 45247
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
La Jolla, California 92093
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
New York, New York 10011
?
mi
from
New York, NY
Click here to add this to my saved trials
Orange, California 92868
?
mi
from
Orange, CA
Click here to add this to my saved trials
Orlando, Florida 32806
?
mi
from
Orlando, FL
Click here to add this to my saved trials